PERFORMANCE IN DELIVERING CLINICAL RESEARCH (Q4, 2015/16)

Research Ethics Committee Reference Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Reason For Closure Of Trial	Comments
07/H1102/84	Sunitinib treatment of renal adjuvant cancer (S-TRAC) A randomised double blind phase 3 study of adjuvant vs placebo in subjects at high risk of recurrent RCC. Study Number: A6181109	Number Agreed	3	3	Not Available / Not Agreed		0	19/06/2015		No date agreed with sponsor.
07/Q1206/53	Clinical Trial Protocol CAMN107A2303 - A phase III multi-center, open-label, randomized study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CM	Number Agreed	5	5	Date Agreed	15/06/2008	5	15/06/2008	Recruitment Finished	Study recruited to time and target.
09/H0405/51	A Phase II Study of Dasatinib therapy in children & adolescents with PH+ leukaemia with resistance or intolerance to Imatinib.	Not Available / Not Agreed			Not Available / Not Agreed			04/10/2014		No target/date agreed with sponsor.
10/H0605/58	Sub Study to study WN25203,using positron emission tomography (PET) with an amyloid tracer to assess changes in amyloid load over time in subjects with Prodromal Alzheimer's Disease	Number Agreed	1	1	Date Agreed	30/09/2012	1	30/09/2012	Recruitment Finished	Study recruited to time and target.
10/H0605/59	Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease (WN25203)	Number Agreed	6	6	Date Agreed	01/09/2013	6	01/09/2013	Recruitment Finished	Study recruited to time and target.
10/H0713/35	An International, multi-center, randomized, controlled trial evaluating the effect of xenon on post-operative delirium in elderly patients undergoing hip fracture surgery	Number Agreed	6	6	Date Agreed	31/10/2014	6	31/10/2014	Recruitment Finished	Study recruited to time and target.
10/H0715/57	A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy	Number Agreed	5	5	Date Agreed	01/11/2011	5	01/11/2011	Recruitment Finished	Study recruited to time and target.
10/H0904/49	A single arm, open-label, multicenter study evaluating the long-term safety, tolerability and efficacy of 0.5mg fingolimod (FTY720) administered oraly once daily in patients with multiple sclerosis	Number Agreed	10	10	Date Agreed	01/12/2011	10	01/12/2011	Recruitment Finished	Study recruited to time and target.
11/EM/0074	A 2-Year, multicenter, double-masked, randomised, parallel study of the safety of LUMIGAN 0.1 mg/mL compared with LUMIGAN 0.3 mg/mL in patients with glaucoma or ocular hypertension	Number Agreed	15	15	Date Agreed	30/09/2014	15	30/09/2014	Recruitment Finished	Study recruited to time and target.
11/LO/0449	A multicenter, global, randomized, double-blind study of axitinib versus placebo in patients with advanced hepatocellular carcinoma following failure of one prior antiangiogenic therapy	Number Agreed	2	2	Date Agreed	30/06/2012	2	30/06/2012	Recruitment Finished	Study recruited to time and target.
11/LO/1369	A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy	Number Agreed	1	1	Date Agreed	31/08/2014	1	31/08/2014	Recruitment Finished	Study recruited to time and target.
11/NW/0298	A multicenter, phase III, open-label, randomized study in previously untreated patients with advanced indolent non Hodgkins Lymphoma comparing GA1O1 (RO5072759) plus chemotherapy with rituximab plus chemotherapy followed by GA101 or rituximab mainten	Number Agreed	2	2	Date Agreed	20/12/2013	2	20/12/2013	Recruitment Finished	Study recruited to time and target.
11/SC/0454	A phase IIIb parallel group, open label study of pegylated interferon alfa-2a monotherapy (PEG-IFN, RO 25-8310) compared to untreated control in children with HBeAg positive chronic hepatitis B	Number Agreed	2	2	Date Agreed	01/11/2014	2	01/11/2014	Recruitment Finished	Study recruited to time and target.

12/LO/0098	A randomized, doubleblind, placebo controlled, multiple dose study to evaluate the safety, tolerability, and efficacy of intravenous administration of secukinumab (AIN457) in patients with asthma not adequately controlled with inhaled corticosteroids and l	Number Agreed	6	6	Date Agreed	01/08/2013	0	01/08/2013	Recruitment Finished	Target of 6 patients was met in October 2013.
12/LO/1823	A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV 1 Infecte	Number Agreed	10	10	Date Agreed	19/12/2013	2	10/10/2013	Recruitment Finished	There were 2 patients recruited.
12/LO/1889	Openlabel,single arm extension study to the doubleblind,randomized, multicenter, placebo controlled,parallel group study comparing the efficacy and safety of 0.5 mg FTY720 administered orally once daily versus placebo in patients with primary progressive m	Number Agreed	6	6	Date Agreed	31/08/2014	6	31/08/2014	Recruitment Finished	Study recruited to time and target.
12/LO/1966	A Phase 3, Randomized, Placebocontrolled, Parallelgroup, Multicenter, Doubleblind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome Refractory to Somatostatin Analog (SSA) Therapy	Number Agreed	1	1	Date Agreed	31/12/2014	1	31/12/2014	Recruitment Finished	Study recruited to time and target.
12/LO/1981	A Randomized, Multicenter, Open-Label Phase III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine Versus Trastuzumab As Adjuvant Therapy For Patients With Her2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologic	Number Agreed	3	3	Date Agreed	01/03/2016	3	04/11/2015	Recruitment Finished	Study recruited to time and target.
12/NW/0137	A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin	Number Agreed	5	5	Date Agreed	03/11/2017	5	16/07/2013	Recruitment Finished	Study recruited to time and target.
12/SC/0538	A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Behavioral Variant Frontotemporal Dementia (bvFTD)	Number Agreed	6	6	Date Agreed	01/01/2014	4	11/12/2014	Recruitment Finished	Target of 6 reached in December 2014.
12/SS/0007	A randomised Phase 2 Placebo-Controlled Study of LY2495655 in Patients with Advanced or Metastic Pancreatic Cancer Receiving Chemotherapy	Number Agreed	4	4	Date Agreed	30/01/2014	2	30/11/2013	Recruitment Finished	Rare disease study. There were 2 patients recruited.
12/SW/0378	Effect of BivaliRudin on Aortic Valve Intervention Outcomes 2/3 (BRAVO 2/3)	Number Agreed	6	6	Date Agreed	02/02/2015	6	20/05/2015	Recruitment Finished	Research Nurse unfortunately had a bereavement and after discussion with the study sponsors , we therefore agreed to postpone start of recruitment. First patient was consented in September 2014; there were 6 patients recruited in total .
12/WM/0373	A randomised trial in new hearing aid users to measure the benefit of using 4 pre-set configurations of hearing aids with self learning characteristics	Number Agreed	50	50	Date Agreed	01/11/2015	60	28/04/2015	Recruitment Finished	Study recruited to time and target.
12/YH/0318	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia	Number Agreed	5	5	Date Agreed	02/07/2014	5	02/07/2014	Recruitment Finished	Study recruited to time and target.
13/EE/0364	A Randomized, Doubleblind, Multicenter Phase 2 Trial of Denosumab in Combination with Chemotherapy as Firstline Treatment of Metastatic Nonsmall Cell Lung Cancer.	Number Agreed	12	12	Date Agreed	31/05/2015	30	21/05/2015	Recruitment Finished	Study recruited to time and target.
13/EM/0348	Safety and Efficacy assessment of Monoprost? (unpreserved latanoprost) in comparison with Lumigan? 0.01 % and Lumigan? 0.03% UD, in patients with primary open angle glaucoma or ocular hypertension, stabilized by Lumigan? 0.01 % with ocular surfac	Number Agreed	6	6	Date Agreed	31/08/2015	4	30/03/2016	Recruitment Finished	Study recruited to time and target.

13/EM/0460	A RANDOMIZED, MULTICENTER, OPEN-LABEL TRIAL COMPARING CHEMOTHERAPY PLUS TRASTUZUMAB PLUS PERTUZUMAB VERSUS CHEMOTHERAPY PLUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2 POSITIVE PRIMARY BREAST CANCER	Number Agreed	6	6	Date Agreed	28/02/2016	3	23/04/2015	Withdrawn By Sponsor	Study closed to recruitment nationally early by the sponsored (closed 22/05/2015) which is why we did not manage to recruit to time and target. This was due to newly available data from the phase III MARIANNE study.
13/LO/0326	A RANDOMIZED, PHASE 3 STUDY OF GANETESPIB IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL ALONE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG ADENOCARCINOMA	Number Agreed	2	2	Date Agreed	30/09/2016	2	31/10/2015	Recruitment Finished	Study recruited to time and target.
13/LO/0671	A Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301	Number Agreed	7	7	Date Agreed	28/02/2014	7	28/02/2014	Recruitment Finished	Study recruited to time and target.
13/LO/1050	A Multicenter, Randomized, OpenLabel, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in FirstLine Treatment of Subjects With Unresectable Hepatocellular Carcinoma	Number Agreed	5	5	Not Available / Not Agreed		0	31/07/2015	Withdrawn By Sponsor	Study closed early by sponsor.
13/LO/1121	A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First Line Treatment in Metastatic Non Small Cell Lung Cancer Patients with Activating EGFR Mutations Who Have Disease Control after an 8 Week Lead In Tre	Number Agreed	4	4	Date Agreed	01/03/2015	5	15/09/2014	Recruitment Finished	Study recruited to time and target.
13/LO/1302	A Phase IIIb randomised, openlabel study of the safety and efficacy of dolutegravir/abacavir/lamivudine once daily compared to atazanavir and ritonavir plus tenofovir/emtricitabine once daily in HIV1 infected antiretroviral therapy naive women.	Number Agreed	4	4	Date Agreed	01/08/2014	4	01/08/2014	Recruitment Finished	Study recruited to time and target.
13/LO/1352	A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AFTER PLATINUM FAILURE	Number Agreed	2	2	Date Agreed	31/03/2014	2	31/03/2014	Recruitment Finished	Study recruited to time and target.
13/LO/1814	A phase III, randomized, controlled, single-blind, multicentre, parallel arm trial to assess the efficacy and safety of Pergoveris? (follitropin alfa and lutropin alfa) and GONAL-f? (follitropin alfa)	Not Available / Not Agreed			Not Available / Not Agreed			28/09/2014		No target/date agreed with sponsor.
13/NI/0188	A singlearm trial to evaluate the effectiveness of PCI of de novo 3vessel disease applying the SYNTAX score II with pressure wire functional assessment and IVUS guidance, using an everolimuseluting stent with biodegradable abluminal coating	Number Agreed	17	17	Date Agreed	31/12/2019	27	13/11/2015	Recruitment Finished	Study recruited to time and target.
13/NW/0363	A Multicenter Openlabel Extension (OLE) Study to Assess the Long term Safety and Efficacy of AMG 145	Number Agreed	8	8	Date Agreed	01/01/2014	0	01/01/2014	Recruitment Finished	There were 2 patients recruited.
13/NW/0778	A double-blind, randomised, placebo-controlled, Phase II study to evaluate ProCervix efficacy to clear HPV 16 and HPV 18 infection in women with normal cytology or ASCUS/LSIL	Number Agreed	1	1	Date Agreed	30/11/2014	1	30/11/2014	Recruitment Finished	Study recruited to time and target.
13/SC/0092	A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312)in patients with secondary progressive multiple sclerosis (Protocol No: CBAF312A230	Number Agreed	6	6	Date Agreed	30/04/2014	6	30/09/2014	Recruitment Finished	Sponsor delays with IMP supply. Target of 6 reached on the following month. A total of 7 patients recruited.
13/SC/0259	A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas. Gilead GS-US-313-0125	Number Agreed	3	3	Date Agreed	31/10/2014	3	31/10/2014	Recruitment Finished	Study recruited to time and target.

13/SC/0383	A Two Part, Randomized Clinical Trial to Study Biomarkers of MK8237 (SCH 900237) Treatment in Subjects with House Dust Mite Induced Allergic Rhinitis or Rhinoconjunctivitis	Number Agreed	20	20	Date Agreed	31/01/2015	20	31/01/2015	Recruitment Finished	Study recruited to time and target.
13/WA/0064	A performance evaluation study of UROSENS Mcm5 ELISA test in the diagnosis of bladder cancer in patients presenting with haematuria and lower urinary tract symptoms with suspicion of malignancy	Number Agreed	250	250	Date Agreed	15/01/2014	227	15/03/2014	Recruitment Finished	Target of 250 patients reached within 10 months; contract stated 8 months.
13/WS/0172	A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL 2)	Number Agreed	8	8	Date Agreed	13/12/2015	0	13/12/2015	Withdrawn By Sponsor	Sponsor closed recruitment early in September 2015.
13/WS/0282	Prospective, single-arm, global multi-center study to evaluate treatment of obstructive superficial femoral artery and/or popliteal lesions wiht a novel paclitaxel coated percutaneous angioplasty ballon.	Number Agreed	10	10	Date Agreed	01/01/2016	13	01/01/2016	Recruitment Finished	Study recruited to time and target.
13/YH/0317	Current Steering to Optimize Deep Brain Stimulation	Number Agreed	4	4	Date Agreed	30/11/2014	4	30/11/2014	Recruitment Finished	Study recruited to time and target.
14/EM/0186	A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis	Number Agreed	2	2	Date Agreed	14/08/2018	0	31/01/2016	Withdrawn By Sponsor	Study closed early without recruitment. No patient satisfied the stringent entry criteria but meanwhile patients have had increased mortality in an arm of the study, so FDA has placed a hold on the drug/all trials and all patients on pacritinib have to come off this drug.
14/EM/1059	A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura	Number Agreed	1	1	Date Agreed	30/09/2016	2	08/01/2016	Recruitment Finished	Study recruited to time and target.
14/EM/1286	A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer	Number Agreed	3	3	Date Agreed	30/11/2016	3	29/10/2015	Recruitment Finished	Study recruited to time and target.
14/EM/1314	Randomized, Blinded, Multicenter, Phase 2 Study Comparing Veliparib Plus FOLFIRI ? Bevacizumab Versus Placebo Plus FOLFIRI ? Bevacizumab in Previously Untreated Metastatic Colorectal Cancer	Number Agreed	3	3	Date Agreed	31/03/2017	1	28/08/2015	Withdrawn By Sponsor	The global target was met much quicker than the sponsors were anticipating and we ended up only actively recruiting for 1 month.? We opened on 20/07/15 and closed on 31/08/15. The early closure wasn?t communicated to us at any stage before we were open so it was out of our control. We were site activated 20/07/2015 and target was 3 by 31/03/2017, so we thought we had 2 years. We have 1 consented, so pro-rata and we were on (above) track. If sponsor had told us recruitment was above target global
14/LO/0521	A prospective, randomized, open label, two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia positive CML after two different durations of consolidation treatment with nilotinib 300mg BID.	Number Agreed	1	1	Date Agreed	01/12/2019	2	12/01/2015	Recruitment Finished	Study recruited to time and target.
14/LO/0665	A Phase III OpenLabel Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK5172/ MK8742 in TreatmentNa?ve Subjects with Chronic HCV GT1, GT4, GT5, and GT6 Infection who are on Opiate Substitution Therapy.	Number Agreed	4	4	Not Available / Not Agreed		4	10/09/2014	Recruitment Finished	Study recruited to time and target.

14/LO/0673	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS 1101 (CAL-101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia.	Number Agreed	7	7	Date Agreed	31/03/2018	5	03/02/2016	Recruitment Finished	
14/LO/0717	A Multicenter Phase 3 Randomized Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukaemia.	Number Agreed	2	2	Date Agreed	12/05/2020	10	21/08/2015	Recruitment Finished	Study recruited to time and target.
14/LO/0882	A PHASE III, OPEN-LABEL, MULTICENTER,RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY	Number Agreed	4	4	Date Agreed	01/06/2015	12	14/04/2015	Recruitment Finished	Study recruited to time and target.
14/LO/1053	A Phase 3 Randomised double blind Active study Evaluating Memelotinib vs Ruxolitinib in subjects with primary Myelofibrosis (PMF) or Post-poly cythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)	Number Agreed	2	2	Date Agreed	01/12/2017	3	30/10/2015	Recruitment Finished	Study recruited to time and target.
14/LO/1381	A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Reformulated Raltegravir 1200 mg Once Daily versus Raltegravir 400 mg Twice Daily, Each in Combination with TRUVADA	Number Agreed	5	5	Date Agreed	30/04/2015	1	08/01/2015	Withdrawn By Sponsor	Study closed to recruitment by sponsor before agreed date to recruit by.
14/NE/1109	Cardiac Resynchronization Therapy Efficacy Enhancements (CRTee)	Number Agreed	5	5	Date Agreed	01/01/2017	1	25/01/2016	Withdrawn By Sponsor	Sponsor closed study early due to global target recruitment being achieved. Site recruited 1/5 patients.
14/NW/0008	Golimumab: A Phase 4, UK Open Label, Single arm Study on its Utilization and Impact in Ulcerative Colitis	Number Agreed	6	6	Date Agreed	31/03/2016	2	09/01/2015	Withdrawn By Sponsor	Study closed to recruitment by sponsor before agreed date to recruit by.
14/NW/0130	A randomised, double blind, multi-center, placebo-controlled study to evaluate the efficacy, safety, and tolerability of NT100 in pregnant women with a history of unexplained recurrent pregnancy loss (RPL)	Number Agreed	20	20	Date Agreed	01/06/2015	21	17/06/2015	Recruitment Finished	Study recruited to time and target.
14/NW/0156	OlympiAD - Olaparib monotherapy V Physicians choice chemotherapy	Number Agreed	1	1	Date Agreed	31/10/2015	1	15/06/2015	Recruitment Finished	Study recruited to time and target.
14/NW/1506	BlueWind system safety and performance in treatment of patients diagnosed with overactive bladder (OAB)	Number Agreed	4	4	Not Available / Not Agreed		4	04/09/2015	Recruitment Finished	Study recruited to target.
14/SC/0037	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, EFFICIACY AND SAFETY STUDY OF GANTENERUMAB IN SUBJECTS WITH MILD ALZHEIMER?S DISEASE	Number Agreed	5	5	Date Agreed	31/01/2016	5	30/09/2015	Recruitment Finished	Study recruited to time and target.
14/SC/0038	PET IMAGING SUBSTUDY ASSOCIATED WITH: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, EFFICIACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH MILD ALZHEIMER?S DISEASE	Number Agreed	5	5	Date Agreed	31/01/2016	7	30/09/2015	Withdrawn By Sponsor	Sponsor closed recruitment window 6 months early. Site recuited 4 patients.
14/SC/0178	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia	Number Agreed	2	2	Date Agreed	31/08/2016	3	20/11/2014	Recruitment Finished	Study recruited to time and target.
14/SC/1014	A Randomized, DoubleBlind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas (The JANUS 1 study)	Number Agreed	2	2	Date Agreed	26/01/2016	2	09/11/2015	Recruitment Finished	Study recruited to time and target.
14/WM/0170	A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis,	Number Agreed	2	2	Date Agreed	01/10/2020	3	12/01/2016	Recruitment Finished	Study recruited to time and target.

14/WM/1056	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic HCV	Number Agreed	6	6	Not Available / Not Agreed		12	19/11/2014	Recruitment Finished	Study recruited 12/6 patients.
14/YH/0049	A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of the Combined Lysis of Thrombus with Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization (CLOTBUST-ER) in Acute Ischemic Stroke.	Number Agreed	10	10	Date Agreed	31/12/2016	8	23/03/2015	Withdrawn By Sponsor	Sponsor closed study early due tosafety data review on 26th March 2015 which concluded futility. Follow up of patients continued until mid-2016. Site recruited 8 patients.
14/YH/1057	A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 24 Weeks in Subjects with Chronic Genotype 3 HCV Infection	Number Agreed	9	9	Not Available / Not Agreed		13	18/11/2014	Recruitment Finished	Study recruited 13/9 patients.
15/LO/0016	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative (?)	Number Agreed	3	3	Not Available / Not Agreed		0	19/10/2015	Withdrawn By Sponsor	Sponsor delays in the lab kit being shipped to site which postponed activation until the 11/08. One patient was eligible but declined to take part. Furthermore, the recruitment early nationally as they achieved their global target sooner than anticipated.
15/LO/0210	An exploratory, open-label, multicenter study to evaluate the safety and efficacy of ATIR, donor T-lymphocytes depleted ex vivo of host alloreactive T-cells, in patients with a hematologic malignancy, who received a CD34-selected (..) cell	Number Agreed	1	1	Date Agreed	15/07/2017	2	30/04/2015	Recruitment Finished	Study recruited to time and target.
15/LO/0652	A Phase 2b Randomized, Active-Controlled, Double-Blind Trial to Investigate Safety, Efficacy and Dose-response of BMS-955176, Given on a Backbone of Tenofovir/Emtricitabine, in Treatment-Naive HIV-1 Infected Adults	Number Agreed	5	5	Date Agreed	31/08/2017	0	14/09/2015	Withdrawn By Sponsor	Sponsor closed recruitment 2 weeks after site got R&D Approval. Recruitment was competitive and study reached full recruitment.
15/LO/0940	A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia	Number Agreed	4	4	Not Available / Not Agreed		0	29/02/2016	Withdrawn By Sponsor	Study terminated early by sponsor due to a change in the risk profile of the study drug idelalisib. The study was terminated for safety reasons.
15/WS/0037	A single-arm, post-market study of the Endo GI Reinforced Reload with Tri-Staple Technology	Number Agreed	30	30	Date Agreed	01/05/2016	28	18/03/2016	Recruitment Finished	Study recruited to time and target.